Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares

Key Points

• Representative Val T. Hoyle sold shares of BioNTech SE (NASDAQ:BNTX) for between $1,001 and $15,000 on August 7th, disclosed in a filing on September 12th.
• BioNTech recently reported a loss of $1.60 earnings per share for the quarter, missing analyst estimates, despite a significant year-over-year revenue increase of 102.6%.
• Analysts have given BioNTech a consensus rating of "Moderate Buy" with price targets ranging between $112.00 and $155.00, indicating a positive outlook for the stock.

Representative Val T. Hoyle (D-Oregon) recently sold shares of BioNTech SE Sponsored ADR NASDAQ: BNTX. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in BioNTech stock on August 7th. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Walgreens Boots Alliance NASDAQ: WBA on 8/27/2025.
• Sold $1,001 - $15,000 in shares of Palo Alto Networks NASDAQ: PANW on 8/19/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of Uber Technologies NYSE: UBER on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Johnson Controls International NYSE: JCI on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Copart NASDAQ: CPRT on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of Tyler Technologies NYSE: TYL on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of United Rentals NYSE: URI on 8/7/2025.

BioNTech Stock Performance

Shares of BNTX traded down $0.09 during mid-day trading on Friday, hitting $96.22. 2,158,031 shares of the company's stock were exchanged, compared to its average volume of 1,235,562. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $129.27. The firm has a market capitalization of $23.13 billion, a P/E ratio of -60.14 and a beta of 1.39. The business's 50 day moving average is $107.34 and its two-hundred day moving average is $103.43. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same period in the previous year, the business posted ($3.36) earnings per share. The firm's revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. On average, equities analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BNTX. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. The Goldman Sachs Group started coverage on shares of BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price for the company. Truist Financial restated a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a research report on Monday, June 2nd. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $134.23.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently made changes to their positions in the stock. Baader Bank Aktiengesellschaft raised its holdings in shares of BioNTech by 6.3% in the second quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company's stock worth $16,032,000 after acquiring an additional 9,040 shares during the last quarter. Swedbank AB acquired a new position in BioNTech in the 1st quarter valued at about $3,415,000. Millennium Management LLC raised its stake in BioNTech by 252.5% in the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company's stock valued at $49,625,000 after purchasing an additional 390,360 shares during the last quarter. OneDigital Investment Advisors LLC acquired a new position in shares of BioNTech in the first quarter valued at approximately $288,000. Finally, GAMMA Investing LLC raised its position in shares of BioNTech by 5,710.8% in the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock valued at $4,884,000 after buying an additional 52,711 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.